Medline (NASDAQ:MDLN) Announces Earnings Results

Medline (NASDAQ:MDLN) issued its earnings results on Wednesday. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12, FiscalAI reports. The company had revenue of $7.86 billion during the quarter.

Here are the key takeaways from Medline’s conference call:

• Positive Sentiment: Third-quarter net sales rose 10% to $7.9 billion, and Adjusted EBITDA increased 12% to $1.0 billion. Growth was broad-based, though EBITDA included an $81 million benefit from tariff refunds.
• Positive Sentiment: Medline raised its 2026 organic sales growth outlook for the third consecutive quarter, to 10%–10.5%, while reaffirming Adjusted EBITDA guidance of $3.3 billion–$3.4 billion, expected near the midpoint.
• Negative Sentiment: Management expects 2027 sales growth in the high single digits but EBITDA growth only in the low to mid-single digits, citing elevated inflation and investment in capacity, operations, and quality. It expects EBITDA growth to return to at least sales growth in 2028.
• Positive Sentiment: Medline reported strong customer signings and said it remains on track for its $1 billion 2026 goal; it is also expanding distribution capacity with four facilities planned or underway and progressing with its first Canadian Prime Vendor rollout.
• Negative Sentiment: The Global Quality Action Plan is a multi-year effort involving third-party assessments and ongoing investment and remediation. Medline is exiting its roughly $60 million home-care-bed business, and management acknowledged other issues could emerge as it assesses its network.

Medline Price Performance

Shares of Medline stock traded up $5.47 on Wednesday, hitting $39.56. The company had a trading volume of 10,933,738 shares, compared to its average volume of 7,674,328. Medline has a 52 week low of $31.37 and a 52 week high of $50.88. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. The company has a market cap of $52.01 billion and a PE ratio of 50.13. The business has a 50-day simple moving average of $34.48 and a 200-day simple moving average of $39.54.

Insider Buying and Selling

In other Medline news, major shareholder Private Ltd Gic sold 2,088,987 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the sale, the insider directly owned 16,453,806 shares in the company, valued at $576,705,900.30. This represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 8,810,954 shares of company stock worth $312,416,990 over the last quarter. 0.81% of the stock is owned by insiders.

Hedge Funds Weigh In On Medline

Several hedge funds have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in Medline during the first quarter worth $30,000. Reyes Financial Architecture Inc. acquired a new position in Medline during the third quarter worth $30,000. NewEdge Advisors LLC increased its position in Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after buying an additional 487 shares in the last quarter.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported third-quarter EPS of $0.44, above the $0.32 analyst consensus, and revenue of $7.86 billion. Coverage also said the company raised its full-year growth outlook, supporting investor optimism about operating momentum. Medline Q3 2026: EPS beats by 27%, full-year growth outlook raised
• Positive Sentiment: Reports highlighted a $1 billion share-buyback plan, which may support per-share results and signal management confidence. Medline posts best intraday gain after Q3 beat, $1B share buybacks
• Positive Sentiment: Health Future renewed its prime-vendor agreement with Medline, providing a sign of continued customer retention. Health Future renews Prime Vendor agreement with Medline
• Negative Sentiment: Some coverage said quarterly profit fell, even as EPS exceeded estimates; Medline reaffirmed its full-year adjusted EBITDA outlook. This tempering detail may limit enthusiasm around the headline beat. Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up
• Negative Sentiment: A law firm announced an investigation concerning alleged product-quality issues and potential securities-law violations. This is an investigation announcement, not a finding of wrongdoing, but it could add legal and reputational risk. MDLN Investigation Reminder

Wall Street Analysts Forecast Growth

MDLN has been the subject of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and set a $47.00 price objective on shares of Medline in a research note on Thursday, August 6th. JPMorgan Chase & Co. cut their target price on Medline from $53.00 to $46.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 12th. Citigroup raised shares of Medline to a “strong-buy” rating in a report on Wednesday, August 5th. Robert W. Baird set a $42.00 price target on shares of Medline in a report on Thursday, August 6th. Finally, Tigress Financial lowered their price target on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average target price of $46.54.

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.